Latest Ratios: P/E Ratio -10.1x · EV/EBITDA N/A · ROE -15.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $85M | $31M | $42M | $97M | $209M | $307M | — | — |
| Enterprise Value | $54M | $-292759 | $28M | $73M | $153M | $131M | — | — |
| P/E Ratio → | -10.10 | — | — | — | — | — | — | — |
| P/S Ratio | 99.17 | 36.02 | 65.73 | — | — | — | — | — |
| P/B Ratio | 1.56 | 0.53 | 0.68 | 0.91 | 1.23 | 1.75 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.34 | 44.11 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.3% | 89.3% | 100.0% | — | — | — | — | — |
| Operating Margin | -3270.9% | -3270.9% | -9511.9% | — | — | — | — | — |
| Net Profit Margin | -1046.4% | -1046.4% | -9084.1% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -15.0% | -15.0% | -68.8% | -54.1% | -38.6% | -30.2% | -34.6% | -104.5% |
| ROA | -13.8% | -13.8% | -62.9% | -50.4% | -36.8% | -29.0% | -32.4% | -81.6% |
| ROIC | -56.4% | -56.4% | -69.8% | -60.7% | -90.0% | — | — | — |
| ROCE | -46.8% | -46.8% | -71.9% | -57.2% | -39.3% | -29.3% | -32.9% | -99.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.54 | -0.22 | -0.23 | -0.33 | -1.00 | -1.03 | -1.15 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -4549.80 | -516.39 | -446.69 |
Net cash position: cash ($31M) exceeds total debt ($176000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.50 | 14.50 | 10.87 | 12.39 | 16.71 | 27.61 | 24.18 | 5.50 |
| Quick Ratio | 14.50 | 14.50 | 10.87 | 12.39 | 16.71 | 27.61 | 24.18 | 5.50 |
| Cash Ratio | 12.96 | 12.96 | 10.50 | 11.87 | 15.73 | 26.76 | 24.00 | 5.11 |
| Asset Turnover | — | 0.01 | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $6M | $5M | $5M | $4M | $4M | $3M | $3M |
Binary clinical trial outcomes
Based on reported figures, RLYB trades at a P/S ratio of 98.80, which appears to be an extreme premium that reflects market anticipation of future clinical success rather than any current fundamental support from the company's nominal, non-recurring revenue streams.
The current valuation multiples are largely disconnected from operational reality, as the company lacks a commercial product to justify such high price-to-sales levels. Investors should monitor the forward EV/EBITDA of 1116.09, which suggests that the market is pricing in a long-term, high-growth trajectory that remains entirely contingent upon successful regulatory milestones.
As reported in financial statements, RLYB's ROIC has consistently remained in negative territory, reaching -19.8% in 2026Q1, which underscores the company's ongoing struggle to generate positive returns while heavily investing in its early-stage monoclonal antibody pipeline.
The persistent negative ROIC is a structural feature of the company's current clinical-stage business model, where capital is consumed to fund R&D rather than deployed to generate immediate returns. This trend suggests that shareholders should not expect capital efficiency until the company transitions from a research-intensive entity to a commercial-stage organization.
According to recent SEC filings, RLYB maintains a current ratio of 12.92 as of 2026Q1, yet this high figure may be misleading as it reflects a rapid depletion of cash reserves rather than an abundance of working capital for long-term operations.
While the current ratio appears robust compared to industrial peers, the underlying cash burn rate indicates that the company's liquidity position is highly vulnerable to the timing of clinical readouts. Investors should interpret this liquidity as a finite window, necessitating either a strategic partnership or dilutive financing to sustain operations beyond the near term.
As indicated by the company's financial data, the use of P/E ratios to evaluate RLYB is fundamentally flawed, as the company's negative earnings of -10.06 TTM obscure the reality that it is a pre-revenue entity focused on clinical development rather than operational profit.
Applying traditional valuation metrics like P/E or EBITDA to a company in this stage of development is misleading, as these ratios fail to account for the binary nature of clinical trial outcomes. Analysts should instead focus on cash-burn-to-milestone metrics, which provide a more accurate assessment of the company's survival and value-creation potential.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RLYB stock.
Rallybio Corporation's current P/E ratio is -10.1x. This places it at the 50th percentile of its historical range.
Rallybio Corporation's return on equity (ROE) is -15.0%. The historical average is -49.4%.
Based on historical data, Rallybio Corporation is trading at a P/E of -10.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Rallybio Corporation has 89.3% gross margin and -3270.9% operating margin.